Stoke Therapeutics, Inc.

STOK · Nasdaq · United States

Share price · STOK

$26.69-5.45 (-16.96%) 3M

close as of 2026-11-18 · 24h delayed · vol 972K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when STOK's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Oct 2026-6.8%
  2. 24 Sep 2026-3.1%

    Nothing announced by STOK that day or the session before.

  3. 23 Sep 2026-10.6%

    Nothing announced by STOK that day or the session before.

  4. 4 Aug 2026+7.1%
  5. 13 Jul 2026-6.1%

    Nothing announced by STOK that day or the session before.

  6. 13 Mar 2026-9.0%

    Nothing announced by STOK that day or the session before.

  7. 19 Feb 2026+10.9%

    Nothing announced by STOK that day or the session before.

  8. 3 Feb 2026+9.8%

    Nothing announced by STOK that day or the session before.

  9. 12 Jan 2026-10.4%
  10. 10 Dec 2025+12.1%

    Nothing announced by STOK that day or the session before.

Share of unusual movement by asset

For each asset, the share of STOK's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zorevunersen
events and moves
116%
STK-002
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—17%
Sessions with no dated event—77%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
SCN1A mRNARNA / oligonucleotide
Dravet Syndrome
Preclinical / Unstaged
OPA1 (wild-type allele expression)RNA / oligonucleotide
Optic Neuropathy
Autosomal Dominant Optic Atrophy

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
March 2027 (1)
ZorevunersenPhase 3Dravet Syndrome
Est. primary completion 2027-03 · NCT06872125 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
ZorevunersenPhase 2Dravet Syndrome
Est. primary completion 2029-03-31 · NCT04740476 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$11M$60M$107M+ $212M short-term inv.$74M-$63M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$9.3M$50M$110M+ $183M short-term inv.$62M-$57M operating cash flowreport ↗
2026-Q1$6.2M$40M$156M+ $188M short-term inv.$50M-$61M operating cash flowreport ↗
2025-Q3$11M$38M$83M+ $165M short-term inv.$38M-$30M operating cash flowreport ↗
2025-Q2$14M$26M$101M+ $146M short-term inv.$23M-$25M operating cash flowreport ↗
2025-Q1$159M$33M$275M+ $83M short-term inv.—$132M operating cash flowreport ↗
2024-Q3$4.9M$22M$150M+ $89M short-term inv.$26M-$22M operating cash flowreport ↗
2024-Q2$4.8M$21M$193M+ $89M short-term inv.$26M-$17M operating cash flowreport ↗
2024-Q1$4.2M$22M$179M$26M-$25M operating cash flowreport ↗
2023-Q3$3.3M$20M$190M+ $25M short-term inv.$25M-$17M operating cash flowreport ↗
2023-Q2-$2.5M$21M$192M+ $39M short-term inv.$31M-$22M operating cash flowreport ↗
2023-Q1$5.2M$20M$190M+ $63M short-term inv.$23M-$21M operating cash flowreport ↗
2022-Q3$2.9M$20M$113M+ $138M short-term inv.$26M-$22M operating cash flowreport ↗
2022-Q2$3.2M$18M$68M+ $208M short-term inv.$25M-$20M operating cash flowreport ↗
2022-Q1$3.0M$18M$84M+ $209M short-term inv.$25M$32M operating cash flowreport ↗
2021-Q3—$14M$149M+ $87M short-term inv.$23M-$15M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$184M$138M$84M+ $200M short-term inv.$1.7M$46M operating cash flowreport ↗

Stoke Therapeutics reported FY 2025 revenue of $184.42M, up 404.4% YoY, with R&D spend of $137.92M, up 54.7% YoY. Cash and equivalents were $84.22M, while total cash, cash equivalents and marketable securities were approximately $391.7M as of December 31, 2025. The company reported a net loss of $6.88M and a quarterly net burn of $6.89M.

The company expects to complete enrollment of 150 patients in the Phase 3 EMPEROR study in Q2 2026, with a data readout anticipated in mid-2027 and a rolling NDA submission planned to initiate in the first half of 2027. Discussions with the FDA are ongoing following a multidisciplinary meeting, and the company continues to explore expedited development and registration pathways for zorevunersen. Management is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company anticipates that its cash position, combined with eligible proceeds from the Biogen collaboration, will fund operations into 2028.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$37M$89M$128M+ $89M short-term inv.$22M-$87M operating cash flowreport ↗
2023-FY$8.8M$82M$191M+ $9.9M short-term inv.$26M-$81M operating cash flowreport ↗
2022-FY$12M$78M$114M+ $116M short-term inv.$25M-$32M operating cash flowreport ↗
2021-FY—$54M$145M+ $75M short-term inv.$21M-$67M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 79 sales ($7.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Ticho Barry · CHIEF MEDICAL OFFICEROpen-market sale6,995$26.38$185KForm 4
2026-11-02Ticho Barry · CHIEF MEDICAL OFFICEROpen-market sale200$26.99$5KForm 4
2026-10-02Allan Jonathan · GENERAL COUNSEL & CORP SECOpen-market sale627$26.33$17KForm 4
2026-10-01Ticho Barry · CHIEF MEDICAL OFFICEROpen-market sale1,051$26.16$27KForm 4
2026-09-23Cumbo Alexander · directorAward / grant (derivative)39,674——Form 4
2026-09-01Ticho Barry · CHIEF MEDICAL OFFICEROpen-market sale3,945$30.51$120KForm 4
2026-09-01Ticho Barry · CHIEF MEDICAL OFFICEROpen-market sale1,600$31.06$50KForm 4
2026-08-18Allan Jonathan · GENERAL COUNSEL & CORP SECOpen-market sale2,716$32.01$87KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 197 reporting institutions held 71.1M shares ($2.2B, 108.7% of shares outstanding).

#InstitutionSharesValue
1RTW INVESTMENTS, LP5,623,525$183.1M
2BlackRock, Inc.5,385,714$175.4M
3FMR LLC5,383,666$175.3M
4Lynx1 Capital Management LP4,763,673$155.1M
5Redmile Group, LLC4,164,120$135.6M
6MORGAN STANLEY3,423,280$111.5M
7BAKER BROS. ADVISORS LP3,336,697$108.6M
8TORONTO DOMINION BANK3,173,258$103.3M
9WELLINGTON MANAGEMENT GROUP LLP3,095,700$100.8M
10BVF INC/IL2,547,557$82.9M
11VANGUARD CAPITAL MANAGEMENT LLC2,355,603$76.7M
12STATE STREET CORP2,276,512$74.1M
13Siren, L.L.C.1,995,347$65.0M
14DEERFIELD MANAGEMENT COMPANY, L.P.1,823,500$59.4M
15JANUS HENDERSON GROUP PLC1,612,781$52.5M